德国的卵巢癌存活率:按阶段和组织型进行全国分析
Victoria Cooley1, Cassia B Trewin-Nybråten2, Kristina Lindemann3
1German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany; Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
概括
卵巢癌的生存率因阶段和组织学而异. 疾病的早期阶段提供了有利的结果,而晚期和特定的组织型,如癌症瘤,则带来了挑战. 诊断后的最初几年对生存至关重要.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 癌症研究 癌症研究
背景情况:
- 以前的卵巢癌存活率研究使用过时的分期和组织学分类.
- 当代治疗实践和详细的组织型分类需要更新的生存分析.
研究的目的:
- 通过阶段和组织学来评估1年,3年,5年和10年的卵巢癌净存活率和过度死亡率.
- 为在2010-2021年期间在德国诊断的侵袭性和边缘性卵巢瘤提供当代的生存数据.
主要方法:
- 利用灵活的参数模型来分析生存数据.
- 包括54,267例侵入性卵巢癌病例和9,478例边缘病例.
- 来自德国癌症登记处的数据,用于2010年1月1日至2021年12月31日期间的诊断.
主要成果:
- 净存活率与阶段有很强的相关性;早期阶段 (I-II) 显示出有利的长期存活率,而晚期阶段 (III-IV) 则表现不佳.
- 第一个阶段的瘤通常具有很高的10年生存率 (≥77%),除了癌性瘤. 10年生存率在46-76% (第二阶段),18-55% (第三阶段) 之间,而第四阶段的5年生存率很差 (15-41%).
- 诊断后的前3年,过度死亡率最高,这表明组织型特异性治疗耐药性和复发. 边缘性瘤的10年生存率很高 (92.9%).
结论:
- 在早期卵巢癌患者中观察到有利的净生存率.
- 在整个组织型和阶段的生存中存在显著的变异性.
- 诊断后的初始期对死亡率至关重要;需要对组织型进行特定的治疗.
更多相关视频
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
08:26Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
Published on: February 23, 2024
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...